Turan Güzel

Turan Güzel

Auto-generated profile, based on publicly available information

Turan Güzel

Department of Pediatric Rheumatology, Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2025 in Trends in Pediatrics
Verified
Journal Article
Open access
PDF file
ŞAŞefika Akyol
Şefika Akyol
TGTuran Güzel
Turan Güzel
AÖAlper Özcan
Alper Özcan
SKSerap Karaman
Serap Karaman
MOMehmet Fatih ORHAN
Mehmet Fatih ORHAN
EÜEkrem Ünal
Ekrem Ünal
Objective: B-cell Non-Hodgkin Lymphoma (B-NHL) is an aggressive malignancy in children requiring prompt multidisciplinary management. This retrospective cohort study aims to evaluate the clinical characteristics, treatment outcomes, and impact of rituximab (RTX) in pediatric B-NHL patients. Methods: We retrospectively analyzed 62 pediatric B-NHL patients treated at tertiary centers. Patient demographics, clinical presentation, histopathological subtypes, disease stage, treatment regimens, and survival outcomes were assessed. Event-free survival (EFS) and overall survival (OS) rates were analyzed based on lactate dehydrogenase (LDH) levels and RTX administration. Results: The mean age at diagnosis was 8.73±4.3 years, with a male predominance (79%). The most common histological subtype was Burkitt lymphoma (BL) (53.2%), followed by diffuse large B-cell lymphoma (DLBCL) (33.8%). Advanced-stage disease (III-IV) was observed in 74.1% of cases. RTX was administered in 72.5% of patients, with a mean of 5.1±2.7 doses. Febrile neutropenia (FEN) was noted in 74.1%, with intensive care unit (ICU) admission required for seven patients. Mortality was observed in 12 (19.3%) patients, including all patients with primary immunodeficiency (PID). The 5-year EFS for the entire cohort was 67.2%, and OS was 81.3%. Patients with LDH 400 U/L (EFS: 49.6%, OS: 70.7%; p=0.004 and p=0.015, respectively). In RTX-treated patients without PID, EFS was 76.5% versus 73.2% in those without RTX, but the difference was not statistically significant (p=0.53). Conclusions: Although not statistically significant, EFS was found to be higher in the RTX-treated group, suggesting that adding RTX to standard chemotherapy regimens may improve survival, particularly for high-risk patients, though its benefit in low-risk cases remains uncertain. Despite improved survival, patients with PID had poor outcomes, likely due to increased infections and disseminated disease. Risk-adapted, targeted treatment strategies are essential for optimizing outcomes in pediatric B-NHL. Further large-scale, randomized controlled trials are needed to confirm the efficacy of RTX in different risk groups and to optimize treatment regimens for pediatric B-NHL.

23 November 2024 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
ŞAŞefika Akyol
Şefika Akyol
EYEbru Yılmaz
Ebru Yılmaz
HTHüseyin Tokgöz
Hüseyin Tokgöz
KKKamuran Karaman
Kamuran Karaman
EPEsra Pekpak
Esra Pekpak
EÜEkrem Ünal
Ekrem Ünal
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disease, with a high mortality if left untreated. In addition, the disease has unique diagnostic challenges. Therefore, despite the existing guidelines on management, current clinical practice data is informative on the course and outcome. Herein, a retrospective chart review study was conducted through the collaboration of six centers, located in central and southeastern Türkiye. The demographical data, laboratory results, and treatment outcomes were evaluated. Eighty-three patients were enrolled in the study. The mean age was 2 years, whereas the median age was 8 months with a range of a minimum of 1 week and a maximum of 12.6 years. Consanguineous marriage, history of sibling death, and familial history of similar disease were determined in 72.2% (n:60), 34.9% (n:29), and 39.8% (n:33) of the patients, respectively. The most common presentation was fever, followed by hepatosplenomegaly on admission. Disease-causing familial HLH variants were identified in 60.2% (n:50) of the patients. Hematopoietic stem cell transplantation (HSCT) was performed in 39.7% (n:33) of the cohort. The 2-year overall survival (OS) rate was 62.4% for the whole group. Comparing the patients who received HSCT and those who did not; the HSCT group had a 2-year OS of 84.7%, which was significantly better than patients who did not receive HSCT had a 2-year OS of 47.1% (p:0.001). Despite the improvement in HLH diagnostics and treatment options over the last decade, early death remains a leading problem for the survival of these patients. Therefore, appropriate assessment of the patients in experienced centers and HSCT are pivotal for better outcomes.

1 January 2025 in Northern Clinics of Istanbul
Verified
Journal Article
Open access
TGTuran Guzel
Turan Guzel
HEHalime Ermistekin
Halime Ermistekin
SGSerdar Goktas
Serdar Goktas
FTFulya Tahan
Fulya Tahan
Anaphylaxis is a life-threatening reaction in every age groups. The causative factors, incidence, and severity of anaphylaxis differ between children and adults. Literature on anaphylaxis during childhood is insufficient. We believe that the data of this study will make important contributions to the literature. A retrospective analysis was conducted on patients aged 0–18 years who were admitted to the Pediatric Allergy Outpatient Clinic at Erciyes University between 2015 and 2021 and diagnosed with anaphylaxis. The majority of the patients were male. Females, however, exhibited greater prevalence during adolescence (p<0.001). Of the total number of patients, 153 (86.9%) had atopy, whereas 25.56% had non-allergic chronic diseases. Food-induced anaphylaxis was identified in 49 (27.84%) patients, drug-induced anaphylaxis in 41 (23.29%), venom-induced anaphylaxis in 62 (35.22%) and idiopathic anaphylaxis in 19. The study observed that anaphylaxis affected several systems, including the skin/mucosa (91.47%), respiratory (72.15%), GI (40.34%), cardiovascular system (20.45%), and central nervous system (17.04%). It was also found that drug-induced anaphylaxis increased the severity of symptoms (p=0.003). Additionally, it was statistically significant that antibiotic-induced anaphylaxis (p=0.002) and wasp sting-induced anaphylaxis (p=0.003) developed within the first minute. Patients received intramuscular adrenaline in 95.46% of cases, while 4.54% did not receive appropriate treatment. Anaphylaxis is a completely reversible reaction when diagnosed correctly and treated promptly. Therefore, it is essential to recognize the common triggers, know the risk factors, and provide patients with appropriate treatment. We believe that this study will contribute to better recognition of deficiencies in the management of anaphylaxis by highlighting important information for anaphylaxis.


16 April 2026 in Journal of Pediatric Orthopaedics
Verified
Journal Article
Closed access
SASelen Duygu Arik
Selen Duygu Arik
BMBengisu Menentoğlu
Bengisu Menentoğlu
PAPinar Prencuva Akyürek
Pinar Prencuva Akyürek
ETEray Tunce
Eray Tunce
SUSila Atamyildiz Uçar
Sila Atamyildiz Uçar
NANuray Aktay Ayaz
Nuray Aktay Ayaz
Background: Chronic nonbacterial osteomyelitis (CNO) is a rare autoinflammatory bone disorder with heterogeneous presentations, and no disease-specific biomarker exists, making diagnosis challenging. Recently, the European Alliance of Associations for Rheumatology (EULAR) and the American College of Rheumatology (ACR) proposed new classification criteria; however, their performance relative to the established Bristol criteria has not been systematically validated. Methods: We conducted a retrospective, multicenter cohort study across 10 pediatric rheumatology centers, including 114 children with CNO and 116 controls with mimicking conditions. Demographic, clinical, laboratory, imaging, and biopsy data were systematically collected. Each participant was assessed according to both the EULAR/ACR classification and the Bristol diagnostic criteria. Sensitivity, specificity, predictive values, likelihood ratios, receiver operating characteristic (ROC) analysis, and agreement statistics were calculated using expert clinical diagnosis as the reference standard. Results: The EULAR/ACR criteria demonstrated 97.4% sensitivity and 81.0% specificity, compared with 79.8% and 80.2% for the Bristol criteria. The negative likelihood ratio was markedly lower for the EULAR/ACR criteria (0.03 vs. 0.25), underscoring their strong rule-out capacity. Concordance between systems was substantial ( κ =0.66). Discordant cases showed that the EULAR/ACR criteria better identified atypical phenotypes such as unifocal or nonclavicular disease. Elevated ESR supported the diagnosis of CNO, whereas profound anemia was almost exclusive to mimicking disorders. Conclusion: The EULAR/ACR criteria provide a more sensitive and inclusive framework for CNO while maintaining robust specificity. Their ability to capture atypical cases may reduce diagnostic delay and unnecessary biopsies, though clinical judgment remains essential in distinguishing CNO from overlapping inflammatory arthritis. Clinical Relevance: Validation of the EULAR/ACR classification criteria may facilitate earlier and more accurate classification of pediatric CNO and reduce unnecessary invasive diagnostic procedures.

14 March 2026 in Pediatric Research
Verified
Journal Article
Open access
PDF file
MDMehmet Akif Dundar
Mehmet Akif Dundar
SESerife Erdem
Serife Erdem
BCBenhur Sirvan Cetin
Benhur Sirvan Cetin
AEAhmet Eken
Ahmet Eken
EUEkrem Unal
Ekrem Unal
BABasak Nur Akyildiz
Basak Nur Akyildiz
Background: Immune dysregulation plays a pivotal role in the pathogenesis of bronchiolitis. This study aimed to investigate the role of immune checkpoint molecules and regulatory cytokines in relation to disease severity. Methods: A prospective cohort of 151 pediatric patients aged 1 month to 2 years was enrolled and classified into control, mild, moderate, and severe bronchiolitis groups. Immune checkpoint molecules (CTLA-4, TIM-3, TIGIT, GARP) and cytokines (IL-2Rα, 4-1BB, TGF-β1, LAG-3, galectin-9) were evaluated in CD4 + FOXP3 + (Treg) and CD4 + FOXP3 − T cells, and in plasma using flow cytometry and ELISA. Results: CD4 + T cell levels decreased with increasing disease severity. Treg frequencies were elevated in mild cases but decreased in moderate and severe cases. CTLA-4 and TIM-3 expression increased on both Treg and non-Treg CD4 + T cells in moderate and severe groups. Soluble PD-1, TIM-3, LAG-3, TGF-β1, and 4-1BB levels were significantly elevated in severe bronchiolitis. Conclusion: Disease severity in bronchiolitis is associated with immune checkpoint dysregulation and an immunosuppressive environment. The observed alterations in T cell subsets and increased expression of CTLA-4 and TIM-3 highlight the potential of these molecules as biomarkers of disease progression. Impact: This study demonstrates that the severity of pediatric bronchiolitis is associated with the dysregulation of immune checkpoint molecules. It adds novel insight into the immunopathogenesis of bronchiolitis by focusing on early immune biomarkers beyond conventional inflammatory parameters. These findings may support risk stratification and contribute to the development of targeted therapies in future pediatric bronchiolitis management.